36 related articles for article (PubMed ID: 37813745)
1. Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Guilhem-Ducléon G; Dalban C; Negrier S; Gravis G; Laguerre B; Chevreau C; Oudard S; Barthelemy P; Ladoire S; Boughalem E; Borchiellini D; Linassier C; Nenan S; Flippot R; Albiges L; Goupil MG
Clin Genitourin Cancer; 2023 Dec; 21(6):643-652. PubMed ID: 37635052
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.
Fitzgerald KN; Lee CH; Voss MH; Carlo MI; Knezevic A; Peralta L; Chen Y; Lefkowitz RA; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha RR; Feldman DR; Motzer RJ
Eur Urol; 2024 May; ():. PubMed ID: 38782695
[TBL] [Abstract][Full Text] [Related]
3. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Massari F; Mollica V; Fiala O; De Giorgi U; Kucharz J; Vitale MG; Molina-Cerrillo J; Facchini G; Seront E; Lenci E; Bourlon MT; Carrozza F; Pichler R; Lolli C; Myint ZW; Kanesvaran R; Torniai M; Rescigno P; Gomez de Liaño A; Zakopoulou R; Buti S; Porta C; Grande E; Santoni M
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38575409
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.
Dogan I; Iribas A; Paksoy N; Vatansever S; Basaran M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S587-S591. PubMed ID: 38384023
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K; Lemelin A; Ernst MS; Wells JC; Saliby RM; El Zarif T; Labaki C; Basappa NS; Szabados B; Powles T; Davis ID; Wood LA; Lalani AA; McKay RR; Lee JL; Meza L; Pal SK; Donskov F; Yuasa T; Beuselinck B; Gebrael G; Agarwal N; Choueiri TK; Heng DYC
Eur Urol; 2024 Jan; ():. PubMed ID: 38290965
[TBL] [Abstract][Full Text] [Related]
6. Serum IgA as a Prognostic Beacon: Anticipating Systemic Therapy Efficacy in Metastatic Clear Cell Renal Cell Carcinoma.
Cui HL; Wu J; Du G; Guan YY; Shi HZ; Zhou AP; Shou JZ
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38767805
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study).
Assié JB; Corre R; Levra MG; Calvet CY; Gaudin AF; Grumberg V; Jouaneton B; Cotté FE; Chouaïd C
Ther Adv Med Oncol; 2020; 12():1758835920967237. PubMed ID: 33403011
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
Hagimoto H; Kashima S; Doi K; Nakayama S; Sano T; Imai S; Yasufuku T; Muramaki M; Yamada Y
IJU Case Rep; 2020 Nov; 3(6):287-290. PubMed ID: 33163928
[TBL] [Abstract][Full Text] [Related]
9. Effect of rechallenge nivolumab in a hemodialysis patient with multiple metastases from a rapidly progressed T1a renal clear cell carcinoma: An autopsy case.
Hanawa K; Sawada N; Yokota Y; Aikawa J; Otake Y; Sugimura K; Shimura H; Mochizuki T; Kira S; Mitsui T
IJU Case Rep; 2024 May; 7(3):202-205. PubMed ID: 38686062
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors to predict the efficacy of surgical interventions against brain metastasis secondary to thyroid cancer.
Yoo J; Kim HJ; Kim SM; Park HH
Eur Thyroid J; 2022 Oct; 11(5):. PubMed ID: 35900775
[TBL] [Abstract][Full Text] [Related]
11. Clear-Cell Renal Cell Carcinoma Metastasis into Pterygomaxillary Fossa - A Case Report.
Migliorelli A; Caranti A; Manuelli M; Bianchini C; Ciorba A; Pelucchi S
Ann Maxillofac Surg; 2023; 13(1):95-97. PubMed ID: 37711533
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Clear Cell Renal Cell Carcinoma Presenting with a Gingival Metastasis.
Ali RA; Mohamed KE
Clin Pract; 2016 Apr; 6(2):847. PubMed ID: 27478584
[TBL] [Abstract][Full Text] [Related]
13. A Brief History of Glandular Therapy: More Than Just Thyroid.
Isaacs LL
Integr Med (Encinitas); 2023 May; 22(2):26-31. PubMed ID: 37363152
[TBL] [Abstract][Full Text] [Related]
14. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Billon E; Dalban C; Oudard S; Chevreau C; Laguerre B; Barthélémy P; Borchiellini D; Geoffrois L; Negrier S; Joly F; Thiery-Vuillemin A; Gross-Goupil M; Rolland F; Priou F; Mahammedi H; Tantot F; Escudier B; Chabaud S; Albiges L; Gravis G
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37813745
[TBL] [Abstract][Full Text] [Related]
15. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Mourey L; Rainho LT; Dalban C; Carril-Ajuria L; Negrier S; Chevreau C; Gravis G; Thibault C; Laguerre B; Barthelemy P; Borchiellini D; Gross-Goupil M; Geoffrois L; Rolland F; Thiery-Vuillemin A; Tantot F; Chaput N; Naigeon M; Teixeira M; Escudier B; Flippot R; Albiges L
Eur J Cancer; 2024 Apr; 201():113589. PubMed ID: 38382153
[TBL] [Abstract][Full Text] [Related]
17. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Courcier J; Dalban C; Laguerre B; Ladoire S; Barthélémy P; Oudard S; Joly F; Gravis G; Chevreau C; Geoffrois L; Deluche É; Rolland F; Topart D; Culine S; Négrier S; Mahammedi H; Tantot F; Jamet A; Escudier B; Flippot R; Albigès L
Eur Urol; 2021 Sep; 80(3):325-329. PubMed ID: 34103181
[TBL] [Abstract][Full Text] [Related]
18. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
